A vs AEE Stock Comparison

Scores Breakdown

Metric	A	AEE
📈 Growth	18/30	0/30
💰 Profitability	16/20	12/20
🏦 Financial Health	7/20	14/20
💵 Valuation	9/20	12/20
⚠️ Risk (lower is better)	7/10	7/10
Overall Score	53/100	41/100

Side-by-Side Summaries

A Analysis	AEE Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory Over eight quarters, Ameren's revenue progressed from $2.173B in 2024 Q2 to $2.176B in 2026 Q1, essentially flat. A standout spike occurred in 2025 Q3 at $2.699B, followed by a dip to $1.782B in 2025 Q4, then a return toward $2.2B. Net income moved unevenly, starting at $457M (Q2 2024) and ending at $358M (Q1 2026), with a peak of $640M in 2025 Q3. 💰 Margins & Cash Flow Operating margins fluctuated, averaging around 24.6%, peaking at 39.3% (2025 Q1) and dipping to 10.2% (2024 Q4). Cash flow: net cash from operating activities was generally positive; investing activities were typically negative, and financing activity provided offsetting support in several quarters. The quarterly cadence yields solid operating cash flow in aggregate, aligning with a capital-intensive utility model. 🛡️ Balance Sheet & Liquidity Total assets run near $49.8B with liabilities around $36.2B and equity of about $13.6B. Long-term debt sits near $19.4B, indicating a moderate debt load for a regulated utility. The balance sheet remains constructive, supported by recurring operating cash flows. ⚠️ Key Drivers & Risks Drivers: Regulated utility framework and stable dividend policy; cash-flow visibility from rate cases. Risks: Regulatory changes and weather-driven demand variability; interest-rate and valuation sensitivity.

A Analysis

AEE Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

Over eight quarters, Ameren's revenue progressed from $2.173B in 2024 Q2 to $2.176B in 2026 Q1, essentially flat. A standout spike occurred in 2025 Q3 at $2.699B, followed by a dip to $1.782B in 2025 Q4, then a return toward $2.2B. Net income moved unevenly, starting at $457M (Q2 2024) and ending at $358M (Q1 2026), with a peak of $640M in 2025 Q3.

💰 Margins & Cash Flow

Operating margins fluctuated, averaging around 24.6%, peaking at 39.3% (2025 Q1) and dipping to 10.2% (2024 Q4). Cash flow: net cash from operating activities was generally positive; investing activities were typically negative, and financing activity provided offsetting support in several quarters. The quarterly cadence yields solid operating cash flow in aggregate, aligning with a capital-intensive utility model.

🛡️ Balance Sheet & Liquidity

Total assets run near $49.8B with liabilities around $36.2B and equity of about $13.6B. Long-term debt sits near $19.4B, indicating a moderate debt load for a regulated utility. The balance sheet remains constructive, supported by recurring operating cash flows.

⚠️ Key Drivers & Risks

Drivers: Regulated utility framework and stable dividend policy; cash-flow visibility from rate cases.
Risks: Regulatory changes and weather-driven demand variability; interest-rate and valuation sensitivity.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"